Navigation Links
PercSys Names David Auth and Howard Palefsky to Its Board of Directors
Date:10/16/2008

PALO ALTO, Calif., Oct. 16 /PRNewswire/ -- Percutaneous Systems, Inc. (PercSys) announced today that it has named two well known medical device entrepreneurs to its Board of Directors. They include David Auth, Ph.D., a medical device executive, educator, innovator and investor, and Howard Palefsky, a leading med-tech venture capitalist.

"PercSys is extraordinarily fortunate to gain the guidance of two of the legendary figures of the medical device industry," stated Robert S. Behl, PercSys founder and chief executive officer. "We look forward to working with these industry leaders as we seek to develop innovative solutions to serious medical problems."

Most recently, Dr. Auth has served as a board member and/or inventor with several medical device companies, including RadioTherapeutics and Novacept prior to their acquisitions, as well as Pathway Medical Technology, Coaptus, Medlogics, Mirabilis, Guided Delivery Systems, Arstasis, and Spineview. Previously, he founded Heart Technology Inc. in 1988 to commercialize his Rotablator invention. Heart Technology became a public company in 1992 and was acquired by Boston Scientific in 1995. Dr. Auth began his career as a professor of engineering at the University of Washington, where he became involved in the embryonic field of bioengineering. He and his graduate students performed seminal studies on multipolar radio frequency hemostasis and fast pulse thermal cautery, leading to the invention of three successful commercial products: the ACMI BICAP, the Olympus HPU, and the Novacept Novasure devices.

Mr. Palefsky has 35 years of experience as an entrepreneur and investor in medical device and pharmaceutical companies. He has been a general partner/managing member of Montreux Equity Partners since 2002 and was a venture partner of Montreux from 1999 to 2002. Prior to joining Montreux, he served as chairman and chief executive officer of NeurogesX. From 1978 to 1997, Mr. Palefsky was the chairman, president, chief executive officer and/or director of Collagen Corporation, guiding it from an early startup to a public company. During his tenure at Collagen, he made a number of successful corporate venture investments, including Target Therapeutics (subsequently sold to Boston Scientific). Mr. Palefsky currently serves on the boards of Windy Hill Medical, Avantis Medical Systems, PulmonX, and NovoStent, and previously held board positions with Questcor, Enteric Medical, and Pro-Duct before their initial public offering or acquisition.

About PercSys

PercSys is developing devices that make urologic and endoscopic procedures easier, less traumatic, and more effective therapeutically. The company is developing a series of unique products for endourology/treatment of kidney stones. The company's initial product, the PercSys Accordion(R) Stone Management Device, was introduced to the market in mid-2007, and a second device in the Accordion family was launched in 2008. Together, these two devices have been used successfully in over 800 endoscopic kidney stone treatments to date. For more information about PercSys and the PercSys Accordion Stone Management Device, please visit http://www.percsys.com.


'/>"/>
SOURCE PercSys
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
2. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
3. New England Peptide Names Director of Chemical Development
4. Codexis Names Vice President, Intellectual Property
5. Genstruct Names Louis Latino VP of Sales
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
8. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
9. ThermoGenesis Names Tiffany Olson to Board of Directors
10. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... ... 24, 2017 , ... It is well established that ligand ... broad application of this cellular target engagement concept to drug discovery has been ... stabilization assays are valuable methods for particular applications, but they can require target-specific ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):